HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dex BTC restrictions?

This article was originally published in The Tan Sheet

Executive Summary

The Army & Air Force Exchange Service has adopted a voluntary plan prohibiting the sale of dextromethorphan (DXM) products to those under the age of 18, the AAFES announces Feb. 9. The policy, enacted Jan. 24, is designed to prevent teenagers from using the drug for recreational purposes. Military members can still purchase DXM products such as Wyeth's Robitussin andAdams' Mucinex over-the-counter at Base Exchange/Post Exchange stores, but will have to show proof of age at check-out. Walgreens enacted a similar nationwide policy in July 2005 in response to an FDA "Talk Paper" highlighting DXM abuse (1"The Tan Sheet" July 4, 2005 p. 12)...

You may also be interested in...



Walgreens Sets Dextromethorphan Age Limit Policy To Curb Abuse

Retailers are working to stay ahead of state legislators looking to place restrictions on products containing the cough suppressant ingredient dextromethorphan (DXM)

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel